Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer, which is the most common and leading cause of cancer-related death in the United States and worldwide (1,2). The clinical benefit of cytotoxic chemotherapy doublets reached a plateau of median overall survival of 7–8 months and a 5-year survival rate of <5% in molecularly unselected patients with metastatic NSCLC in 2000 (3).